

GENERAL INFORMATION

MEETING VENUE

STARHOTELS EXCELSIOR
V.le Pietramellara, 51
40121 Bologna
Ph. +39 051 246178
www.starhotels.com

ITALIAN CME

The application for Italian CME has been made as follows:

- Provider Studio ER Congressi SRL - ID 828-175025
- No. 7 CME credits for physicians
(disciplines: hematology and oncology)
- Educational objective: "guidelines-protocols-procedures".

SCIENTIFIC SECRETARIAT

Prof. Pier Luigi Zinzani
Istituto di Ematologia
"Lorenzo e Ariosto Seràgnoli"
Università degli Studi di Bologna
Via Massarenti, 9 - 40138 Bologna
E-mail: pierluigi.zinzani@unibo.it

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna - Italy
Ph. +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

The Evolving Role of Brentuximab Vedotin in CD30+ Lymphomas

BOLOGNA
FEBRUARY 20, 2017
Starhotels Excelsior



Unrestricted Educational Grant of



Scientific Coordinator:
Pier Luigi Zinzani

09.00 am Welcome and Introduction

P.L. Zinzani (Bologna)

09.15 am **SESSION I**

The therapeutic algorithm in Hodgkin's Lymphoma

Chairmen: *A. Santoro (Rozzano - MI), P.L. Zinzani (Bologna)*

- **New insights in the first salvage setting**
P.L. Zinzani (Bologna)
- **Second salvage treatment: new frontiers**
A. Pinto (Napoli)
- **How to optimize the post ASCT treatment**
A. Younes (New York, USA)
- **Therapeutic options for R/R post ASCT patients**
R. Chen (Duarte, USA)
- **What options after Brentuximab Vedotin**
P. Corradini (Milano)
- **Real life data on the use of Brentuximab Vedotin**
P.L. Zinzani (Bologna)

11.30 am *Coffee break*

11.45 am **LECTURE**

Treatment options in elderly patients with Hodgkin's Lymphoma

A. Forero-Torres (Birmingham, USA)

12.15 pm **DEBATE**

The appropriate use of Brentuximab Vedotin in the post ASCT setting

Chairman: *A. Pinto (Napoli)*

- **As standalone therapy**
A. Younes (New York, USA)
- **As bridge to allogeneic transplant**
R. Chen (Duarte, USA)

01.00 pm **Clinical case reports on:**

Chairman: *U. Vitolo (Torino)*

- **Brentuximab Vedotin in Hodgkin lymphoma: the pre-autologous transplantation setting**
A. Broccoli (Bologna)
- **Brentuximab Vedotin as opportunity for an integrating approach in a very high risk Hodgkin lymphoma patient**
F. Merli (Reggio Emilia)
- **Brentuximab Vedotin as consolidation therapy after autologous hemopoietic stem cells transplantation in a patient with Hodgkin lymphoma**
M. Cantonetti (Roma)

02.00 pm *Lunch*

03.00 pm **SESSION II**
CD30+ T-cell lymphomas

Chairman: *M. Martelli (Roma)*

Overview of the use of Brentuximab Vedotin
P.L. Zinzani (Bologna)

03.30 pm **Clinical case reports on:**

Chairman: *M. Martelli (Roma)*

- **Brentuximab Vedotin in ALCL: experience of Oncohematology Unit, Terni**
R. Martiniani (Terni)
- **Durable long-term remission of CD30+ anaplastic lymphoma in second relapse treated with Brentuximab Vedotin**
S. Hohaus (Roma)
- **Safety and efficacy of long term Brentuximab Vedotin therapy in an AIDS patient affected by Anaplastic Large T Cell Lymphoma**
F. De Angelis (Roma)

04.30 pm **CME evaluation questionnaire**

P.L. Zinzani (Bologna)

05.00 pm **Conclusions and Arrivederci**

P.L. Zinzani (Bologna)